BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 16682614)

  • 1. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries.
    Lee CW; Suh J; Lee SW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 May; 69(6):821-5. PubMed ID: 17191211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries.
    Lee CW; Park DW; Lee BK; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2006 Feb; 97(4):506-11. PubMed ID: 16461047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.
    Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):569-73. PubMed ID: 17442204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.
    Migliorini A; Moschi G; Vergara R; Parodi G; Carrabba N; Antoniucci D
    Catheter Cardiovasc Interv; 2006 Mar; 67(3):344-8. PubMed ID: 16489559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes].
    Byrne R; Iijima R; Mehilli J; Pache J; Schulz S; Schömig A; Kastrati A
    Rev Esp Cardiol; 2008 Nov; 61(11):1134-9. PubMed ID: 19000488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions.
    Lee CW; Park KH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2006 Oct; 98(7):918-22. PubMed ID: 16996874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents.
    Elezi S; Dibra A; Mehilli J; Pache J; Wessely R; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Oct; 48(7):1304-9. PubMed ID: 17010786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
    Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
    Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of lesions with a high risk of stenosis. Comparative study in 300 patients of rapamycin- and Paclitaxel-eluting polymer-based stents, and bare metal stents].
    de la Torre Hernández JM; Sainz Laso F; Ruisánchez C; Zueco J; Figueroa A; Colman T
    Rev Esp Cardiol; 2005 Mar; 58(3):262-9. PubMed ID: 15766448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.
    Holmes DR; Leon MB; Moses JW; Popma JJ; Cutlip D; Fitzgerald PJ; Brown C; Fischell T; Wong SC; Midei M; Snead D; Kuntz RE
    Circulation; 2004 Feb; 109(5):634-40. PubMed ID: 14769686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and predictors of recurrent restenosis following implantation of drug-eluting stents for in-stent restenosis.
    Lee CW; Park CB; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 Jan; 69(1):104-8. PubMed ID: 17139669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
    Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
    Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.
    Jeong YH; Hong MK; Lee CW; Park DW; Kim YH; Kim JJ; Park SW; Park SJ
    Int J Cardiol; 2008 Mar; 125(1):36-40. PubMed ID: 17521753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis.
    Habara S; Mitsudo K; Goto T; Kadota K; Fujii S; Yamamoto H; Kato H; Takenaka S; Fuku Y; Hosogi S; Hirono A; Yamamoto K; Tanaka H; Hasegawa D; Nakamura Y; Tasaka H; Otsuru S; Okamoto Y; Yamada C; Miyamoto M; Inoue K
    Heart; 2008 Sep; 94(9):1162-5. PubMed ID: 18032460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-eluting stent showed better one-year outcomes than paclitaxel-eluting stent in a real life setting of coronary intervention in Koreans.
    Suh JW; Park JS; Cho HJ; Kim MS; Kang HJ; Cho YS; Koo BK; Chung WY; Youn TJ; Chae IH; Choi DJ; Kim HS; Sohn DW; Oh BH; Park YB
    Int J Cardiol; 2007 Apr; 117(1):31-6. PubMed ID: 17292498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.